Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA warns consumers about Que She

This article was originally published in The Tan Sheet

Executive Summary

FDA warns consumers to stop using the weight-loss capsules Que She and consult health care providers because the product contains undeclared active pharmaceutical ingredients that could endanger people with heart conditions. Undeclared ingredients include the Rx weight-loss ingredient sibutramine, which can increase the risk of heart attack and stroke, and the stimulant fenfluramine, which was removed from the U.S. market in 1997 after studies showed it damaged heart valves. The Rx beta blocker propranolol and the stimulant ephedrine also were found in the capsules and pose a risk to people with heart conditions, FDA said July 8. Principal Deputy Commissioner Josh Sharfstein said removing "spiked" supplements from the market is a priority (1"The Tan Sheet" Oct. 26, 2009)

You may also be interested in...

Sharfstein Says Spiked Products Top FDA Supplement Enforcement Goals

FDA Principal Deputy Commissioner Josh Sharfstein says that two to-do lists sit on his desk - one of urgent priorities that the agency must address immediately and one of important tasks that can wait

Device Week, 27 February 2020 – The Risky Business Of Bringing ISO 14971:2019 Into Quality Systems

On this week’s podcast, executive editor Shawn M. Schmitt shares expert tips and advice on how device makers can integrate the recently revised international risk management standard ISO 14971 into their quality systems.

Start-Up Snapshot: Alpha Tau Hopes For A Breakthrough In Radiotherapy

Alpha Tau is looking to change the global radiation therapy paradigm. The Israeli start-up is developing Alpha DaRT, a novel technology for delivering alpha radiation for local tumor destruction.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts